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Abstract 
Purpose: Radiation dose escalation for prostate cancer improves biochemical control but is limited by toxicity. 
Magnetic resonance spectroscopic imaging (MRSI) can define dominant intraprostatic lesions (DIL). This phase I study 
evaluated dose escalation to MRSI-defined DIL using high-dose-rate (HDR) brachytherapy. 
Material and methods: Enrollment was closed early due to low accrual. Ten patients with prostate cancer (T2a-3b, 
Gleason 6-9, PSA < 20) underwent pre-treatment MRSI, and eight patients had one to three DIL identified. The eight 
enrolled patients received external beam radiation therapy to 45 Gy and HDR brachytherapy boost to the prostate of 
19 Gy in 2 fractions. MRSI images were registered to planning CT images and DIL dose-escalated up to 150% of pre-
scription dose while maintaining normal tissue constraints. The primary endpoint was genitourinary (GU) toxicity. 
Results: The median total DIL volume was 1.31 ml (range, 0.67-6.33 ml). Median DIL boost was 130% of prescrip-
tion dose (range, 110-150%). Median urethra V120 was 0.15 ml (range, 0-0.4 ml) and median rectum V75 was 0.74 ml 
(range, 0.1-1.0 ml). Three patients had acute grade 2 GU toxicity, and two patients had late grade 2 GU toxicity. 
No patients had grade 2 or higher gastrointestinal toxicity, and no grade 3 or higher toxicities were noted. There were 
no biochemical failures with median follow-up of 4.9 years (range, 2-8.5 years). 
Conclusions: Dose escalation to MRSI-defined DIL is feasible. Toxicity was low but incompletely assessed due to 
limited patients’ enrollment. 
J Contemp Brachytherapy 2018; 10, 3: 193–201 
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Purpose 
Multiple randomized trials have shown that escalat-
ing the dose of external beam radiation therapy (EBRT) 
beyond the historical standard of 65-70 Gy improves bio-
chemical control of localized prostate cancer [1,2,3,4,5,6]. 
However, higher doses are limited by increased rates 
of gastrointestinal (GI) and genitourinary (GU) toxicity 
[2,4,5]. The intrinsic conformity of high-dose-rate (HDR) 
brachytherapy allows for dose escalation beyond what is 
safely achievable with external beam radiation techniques 
[7,8]. HDR brachytherapy has the additional advantage of 
hypofractionation, especially effective in prostate cancer 
due to its low alpha/beta ratio [9,10]. Accordingly, trials 
using brachytherapy boosts show improvement in bio-
chemical control over dose-escalated external beam radia-
tion alone [11,12,13,14]. However, further dose escalation 
to the entire prostate using brachytherapy has previously 
been limited by normal tissue toxicity, particularly urinary 
toxicity associated with dose to the urethra [15,16,17]. 
Due to the multifocal nature of prostate cancer, the 
conventional assumption in dose escalation trials has 
been that the entire gland must receive a high-dose. 
However, histopathologic studies have shown that a sin-
gle or few dominant intraprostatic lesions (DIL) comprise 
the large majority of the tumor burden yet are typically 
< 10% of the total gland volume [18,19]. Magnetic reso-
nance imaging (MRI) with spectroscopy (MRSI) allows 
for identification of DIL with high accuracy and repro-
ducibility, providing a basis for image-guided therapy 
[20,21,22]. Dosimetric studies also have demonstrated the 
feasibility of focally increasing DIL dose to 120-150% of 
the whole prostate prescription dose while maintaining 
normal tissue dose constraints using inverse-planned 
HDR brachytherapy [23,24,25]. 
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With this background, the present study was opened 
in 2008 to further investigate dose escalation to MRSI- 
defined DIL using inverse-planned HDR brachytherapy, 
in addition to whole prostate brachytherapy and EBRT. 
We report results of this phase I trial. 
Material and methods 
Single-arm phase I trial enrolled patients with biopsy- 
proven prostate adenocarcinoma. Planned total accrual 
was 25 patients. All patients were staged by the National 
Comprehensive Cancer Network (NCCN) guidelines and 
were free from nodal or distant metastatic disease. Eligible 
patients had intermediate- or high-risk localized prostate 
cancer within the following groups: clinical stage T2a-c, 
Gleason score 2-6, and prostate-specific antigen (PSA) 
10-20 ng/ml; clinical stage T3a-b, Gleason score 2-6, and 
PSA ≤ 20; or clinical stage T2a-3b, Gleason score 7-10, and 
PSA ≤ 20.  No prior radiation, prostate-ablative therapy, 
or androgen deprivation therapy (ADT) was permitted 
before study enrollment due to effects on prostate anato-
my and metabolism [26]. Written informed consent was 
obtained from all subjects following a protocol approved 
by the institutional Committee of Human Research 
(10-04222) and the Department of Defense Human Re-
search Protections Office (A-12494). 
The primary outcome measure was the occurrence 
of GU toxicity scored using the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
(CTCAE version 4) grading criteria. Preliminary experi-
ence indicated < 5% grade 3 or higher GU toxicity and ap-
proximately 15% grade 2 or higher GU toxicity occurring 
within 9 months after completing radiotherapy (acute GU 
toxicity) [27]. Therefore, for this trial if > 4 of 25 patients 
(> 16%) experienced grade 2 or higher GU toxicity with-
in 9 months after completing radiotherapy, the treatment 
would be considered unacceptable and accrual discon-
tinued. The upper bound of the exact 95% confidence in-
terval for such toxicity is 33%. In addition, if at any time 
≥ 2 patients experienced grade 3 or higher acute GU tox-
icity, accrual would be stopped. 
After enrollment, patients underwent MRI of the pros-
tate. Images were obtained using a 3T system with pelvic 
and endorectal radiofrequency coils, using previously de-
scribed sequences to acquire T1-weighted, T2-weighted, 
and three-dimensional spectroscopic data on a 12 × 8 × 8 
grid with 5.4 mm cubic voxels [28]. Additional T2-weight-
ed images were acquired without the endorectal coil, al-
lowing for deformable registration to treatment planning 
images [28,29]. Spectroscopic voxels were scored using 
a standardized system from 1-5 with 5 representing the 
highest probability of malignancy [30]. A DIL was defined 
as contiguous voxels with a score of 4 or 5. 
After imaging, treatment began with ADT if pre-
scribed by the treating physician, comprised of oral bi-
calutamide 50 mg daily and intramuscular leuprolide 
7.5 mg monthly. All patients received EBRT to the whole 
prostate and seminal vesicles. Pelvic lymph nodes were 
also included in the treatment volume if the risk of nodal 
involvement was estimated at > 15% [31]. EBRT was de-
livered to a dose of 45 Gy in 25 daily fractions. 
One to three weeks before or after EBRT, HDR tempo-
rary brachytherapy was performed using a 192-Ir source 
administered via transperineal catheters. All implants were 
comprised of 16 catheters inserted into the prostate using 
real-time transrectal ultrasound guidance as previously 
described [32]. For all patients, 16 catheters were used re-
gardless of prostate size for consistency based on a prior 
modelling study [33]. After implantation, patients under-
went pelvic computed tomography (CT) with 2-3 mm 
slice thickness for treatment planning and simulation. 
On the treatment planning CT, the treating physician de-
lineated the whole prostate clinical target volume (CTV) 
without margin and the organs at risk (OAR) includ-
Fig. 1. Example treatment plan of patient treated with 150% boost of dominant intraprostatic lesions (DIL) in left peripheral 
zone. Shaded areas are prostate clinical target volume (CTV), urethra, DIL, and rectum. Isodose lines are 50%, 100%, and 150% 
of prescription dose. A) treatment planning computed tomography (CT). B) T2-weighted magnetic resonance imaging with 
DIL outline registered to treatment planning CT
BA
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ing the intraprostatic urethra, periprostatic rectum, and 
periprostatic bladder. The DIL volume as defined on the 
pre-treatment endorectal coil MRSI was transformed by 
non-linear local weighted-mean registration with mu-
tual information to the pre-treatment MRI without en-
dorectal coil, as previously reported [28]. This was then 
transformed by rigid body registration to the treatment 
planning CT (Figure 1). Both transformation steps have 
registration errors of < 2 mm [28,29]. No planning mar-
gin was used for the focal DIL dose-escalation, as the 
entire prostate was receiving a therapeutic dose. Treat-
ment planning was performed using inverse planning 
with simulated annealing (IPSA; Oncentra Brachy, Elek-
ta, Sweden) [34]. Treatment planning goals were defined 
by dose-volumes normalized to the prescription dose, 
where Dx is the minimum dose to x% of the target vol-
ume, or where Vx is the volume encompassing x% of the 
prescription dose. Target goals were whole prostate CTV 
D90 ≥ 100% prescription dose and a simultaneous boost to 
the DIL D90 up to 150% while maintaining OAR dose-vol-
ume constraints [23]. OAR constraints were as follows: 
urethra V120 ≤ 1 ml and V150 = 0 ml; rectum V75 ≤ 1 ml; 
bladder V75 ≤ 1 ml. All patients received a whole prostate 
CTV prescription dose of 9.5 Gy × 2 fractions (19 Gy total) 
at least 6 hours apart using a single implant session. 
For this study, acute and late genitourinary (GU) and 
gastrointestinal (GI) toxicity were graded by the CTCAE 
version 4. Patient-reported outcomes included GU and 
GI symptoms measured using the International Prostate 
Symptom Score (IPSS) and the Sexual Health Inventory 
for Men (SHIM), which were obtained pre-treatment, one 
month, 3 months, 6 months, 9 months, and 12 months 
post-treatment [35,36]. Patient reported outcomes includ-
ed subscales from the Extended Prostate Cancer Index 
Composite for Clinical Practice (EPIC-CP) for overall uri-
nary function, bowel function, and sexual function, collect-
ed at 6 months and 12 months post-treatment [37]. Disease 
outcomes included PSA nadir (lowest observed PSA after 
completion of radiation and hormonal therapy before any 
PSA rise), freedom from biochemical failure (FFBF) by the 
ASTRO Phoenix definition (nadir +2 ng/ml), cause-spe-
cific death, and death due to any cause. Patient records 
were cross-referenced to the institutional cancer registry 
to obtain information from other institutions. 
Results 
Trial enrollment was open from June 2008 to January 
2011. Seventeen patients were assessed for eligibility, and 
10 underwent pre-treatment prostate MRSI. Of the 7 pa-
tients who were excluded, 5 did not satisfy the eligibil-
ity criteria and 2 declined enrollment. Of the remaining 
10 patients who underwent imaging, one patient was ex-
cluded due to no DIL identified on MRSI, and one patient 
was excluded due to technical imaging error, leaving eight 
patients eligible for DIL dose escalation per study proto-
col (Figure 2). Clinical characteristics are listed in Table 1. 
The median age was 61, and median pre-treatment PSA 
was 9.9 ng/ml (range, 1.0-19.5 ng/ml). Five patients were 
NCCN unfavorable intermediate-risk, two were standard 
high-risk, and one was very high-risk (T3b and Gleason 
score 5+4). All patients received EBRT per protocol with 
Fig. 2. Eligibility and inclusion flowchart
Assessed for eligibility (n = 17)
Underwent MRSI imaging (n = 10)
Included (n = 8) 
Excluded (n = 7) 
Ineligible due to prior ADT use (n = 1) 
Ineligible due to prior radiation therapy (n = 1) 
Ineligible due to PSA level (n = 1) 
Ineligible due to metastatic disease (n = 2) 
Declined enrollment (n = 2)
Excluded (n = 2) 
No DIL visible on MRSI (n = 1) 
Technical imaging error (n = 1) 
Started ADT (n = 5) 
Short term ADT (4 months) (n = 4) 
Long term ADT (24 months) (n = 1)
Received prostate and seminal vesicle EBRT (n = 3)
Received whole pelvis EBRT (n = 5) 
Received brachytheapy (n = 8) 
Completed follow-up (n = 8) 
ADT – androgen deprivation therapy, PSA – prostate-specific antigen, MRSI – magnetic resonance imaging with spectroscopy, DIL – dominant intraprostatic lesions, 
EBRT – external beam radiation therapy
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45 Gy in 25 fractions to the prostate and seminal vesicles. 
In five patients, the treatment fields also included the 
pelvic lymph nodes; they received ADT starting before 
EBRT. Four patients received ADT for 4 months duration 
(three intermediate- and one high-risk patient), and one 
for 24 months duration (very high-risk patient). 
All patients received HDR brachytherapy per proto-
col. Imaging and dosimetric details are listed in Table 2. 
The median prostate volume by MRI was 34.3 ml (range, 
17.6-75.3 ml). Three patients had a single DIL, four pa-
tients had two DILs, and one patient had three DILs. 
The median total DIL volume was 1.31 ml (range, 0.67-
6.33 ml), which was a median of 5.0% of the total prostate 
volume (range, 1.4-18.2%). The median prostate V100 was 
95.7% (range, 92.3-97.3%), and median V150 was 32.2% 
(range, 29.5-37.0%). Five patients received DIL boost 
to 130%, one patient to 110%, one to 125%, and one to 
150% (defined as ≥ 90% coverage). The actual median D90 
across patients was 132% of prescription dose (range, 110-
151%). All OAR constraints were achieved in all patients. 
The median duration of the entire radiation treatment 
course was 7.4 weeks (range, 6.1-9.1 weeks). The median 
time from MRI to brachytherapy was 10.9 weeks (range, 
6.6-23.7 weeks). 
Toxicity results are represented in Figure 3. Three 
patients had acute grade 2 GU toxicity consisting of 
nocturia, urgency, and obstructive symptoms. Four pa-
tients had acute grade 1 GU toxicity of increased urinary 
frequency. Two patients had late grade 2 GU toxicity at 
1-year post-treatment: 1 patient with a urethral stricture 
requiring urethral dilation, and 1 patient with dysuria/
hematuria requiring oral anti-inflammatory medications. 
One of the patients with late grade 2 GU toxicity also had 
acute grade 1 GU toxicity, and the other had no acute GU 
toxicity. No patients had any acute or late GU toxicity of 
grade 3 or higher. For GI toxicity, 4 patients had acute 
grade 1 GI toxicity of diarrhea. One patient with acute GI 
toxicity also had late grade 1 GI toxicity of diarrhea per-
sisting beyond 9 months post-treatment. No patient had 
any acute or late GI toxicity of grade 2 or higher. 
Median scores and changes from pre-treatment for 
IPSS and SHIM are reported in Table 3. On the IPSS 
questionnaire for urinary symptoms (possible 0-35 with 
higher scores representing more symptoms), the median 
pre-treatment score was 7.5 (range, 3-13). IPSS was in-
creased from pre-treatment by a median of 6.5 at 1-month 
post-treatment and by a median of 1 at 3 months post 
treatment, but by 6, 9, and 12 months post-treatment, 
the median change in IPSS was the same or better than 
pre-treatment IPSS (Figure 4). On the SHIM scale for 
sexual function (possible 1-25 with higher scores repre-
senting better function), the median pre-treatment score 
was 18.5 (range, 1-25). SHIM scores decreased by a me-
dian of 3 at 1-month post-treatment and by a median 
of 8 at 3 months post-treatment. The median change in 
SHIM was negative for all post-treatment time points. 
At 12 months post-treatment, the three patients who did not 
receive ADT had SHIM scores of 6 (-8 from pre-treatment), 
8 (-9 from pre-treatment), and 25 (same as pre-treatment). 
Subscales from the EPIC-CP prostate symptoms 
quality of life questionnaire were administered at 6 and 
12 months after radiation therapy [37]. Patients were 
asked how much of a problem overall urinary, bowel, and 
sexual function had been for them over the last 4 weeks, 
using a 5-level scale ranging from 0 (no problem) to 
4 (big problem). Of the 8 enrolled patients, 6 completed the 
questionnaire at 6 months after radiation, and 4 complet-
ed the questionnaire at 12 months after radiation. Results 
Table 3. Median scores and changes from pre-treatment for the International Prostate Symptom Score (IPSS) 
and the Sexual Health Inventory for Men (SHIM)
Pre-treat 1 month 3 months 6 months 9 months 12 months
IPSS 
n 8 8 8 7 7 8
Score 7.5 (3, 13) 15.5 (5, 20) 10 (2, 19) 7 (2, 22) 6 (2, 23) 7.5 (2, 16)
Change N/A +6.5 (–6, +15) +1 (–10, +9) +0 (–7, +12) –2 (–6, +10) –2 (–4, +9)
SHIM 
n 8 7 6 6 6 7
Score 18.5 (1, 25) 18 (1, 25) 7.5 (2, 25) 5.5 (1, 23) 13 (1, 25) 8 (1, 25)
Change N/A –3 (–23, +4) –8 (–17, +2) –3 (–16, +1) –0.5 (–13, +1) –6 (–23, +1)
Values are written as median (minimum, maximum); IPSS – International Prostate Symptom Score; SHI – the Sexual Health Inventory for Men 
N
um
be
r o
f p
at
ie
nt
s
8
7
6
5
4
3
2
1
0
 Acute Late Acute Late
 Genitourinary toxicity Gastrointestinal toxicity
Grade       0         1         2
Fig. 3. Treatment toxicity by grade, CTCAE version 4 
Journal of Contemporary Brachytherapy (2018/volume 10/number 3)
Christopher H. Chapman, Steve E. Braunstein, Jean Pouliot, et al.198
are presented in Table 4. For urinary and bowel function, 
no patient responded higher than 2 (small problem) at any 
time point, and 3 patients responded 0 (no problem) at both 
6 and 12 months. For sexual function, 1 patient responded 
4 (big problem) at 6 months and 2 responded 4 (big prob-
lem) at 12 months, but the remainder responded 0-2. 
The median PSA nadir was 0.12 ng/ml (range, 0.01-
0.66 ng/ml). The median time to nadir after completing 
all radiation therapy was 40.5 months (range, 12.1-102.8 
months). There was one outlier who reached a relative na-
dir of 0.21 ng/ml after 14.7 months before rising again, 
but then achieved a PSA of 0.01 with later follow-up at 
102.8 months. Other than this, the longest time to PSA 
nadir was 58.7 months. For the three patients not receiv-
ing ADT, PSA nadirs were 0.13, 0.21, and 0.10 ng/ml, 
decreased from pre-treatment PSAs of 4.29, 5.50, and 
1.00 ng/ml, respectively. The times to PSA nadir for 
these patients not receiving ADT were 47.4 months, 14.7 
months, and 43.1 months, respectively. After a median of 
4.9 years of available PSA follow-up (range, 2-8.5 years), 
there were no biochemical failures. Survival data were 
available with a median follow-up of 6.7 years (range, 
4.5-8.7 years). As of last follow-up, there were no deaths 
from any cause. 
Discussion 
This trial demonstrates clinical feasibility of dose esca-
lation to MRSI-defined DIL using inverse-planned HDR 
brachytherapy. The level of dose escalation was tailored 
to maintain OAR dose constraints, and the majority of 
patients achieved DIL boosts ≥ 130% of prescription dose 
without any OAR dose constraint violations. The primary 
adverse effect was urinary toxicity, with 3 patients expe-
riencing acute grade 2 GU toxicity. No grade 3 or higher 
toxicities by CTCAE criteria were noted. Two patients ex-
perienced late urinary toxicities requiring interventions; 
however, these resolved without permanent organ dys-
function. Acute urinary symptoms were generally tempo-
rary, as demonstrated by IPSS returning to near pre-treat-
ment baseline or better by 6 months post-treatment for 
most patients, similar to other studies using EBRT plus 
HDR brachytherapy [38,39,40]. By 12 months post-treat-
ment, all patients except one had IPSS within 4 points of 
their pre-treatment score, which is within the test-retest 
variability for IPSS [41]. While the study was ended ear-
ly due to poor accrual, the pre-defined toxicity threshold 
to end accrual of > 4 patients having grade 2 or higher 
toxicity by 9 months post-treatment was not met. How-
ever, the study was very close to reach the pre-defined 
safety endpoint, as only 1 of the remaining 17 planned 
patients could have had grade 2 or higher GU toxicity to 
remain below the safety threshold. Thus, we consider the 
study inconclusive for the primary endpoint of toxicity. 
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Fig. 4. Change in IPSS from pre-treatment score by indi-
vidual patient and median change up to 12 months post- 
treatment
Table 4. Response to overall function subscales of EPIC-CP at 6 and 12 months after radiation therapy. Patients 
were asked how much of a problem urinary, bowel, and sexual function had been over the last 4 weeks. 0 = no 
problem, 1 = very small problem, 2 = small problem, 3 = moderate problem, 4 = big problem. NR – no response
Patient 6 months 12 months
Urinary Bowel Sexual Urinary Bowel Sexual
1 NR NR NR NR NR NR
2 0 2 1 NR NR NR
3 0 0 4 0 0 4
4 1 1 2 NR NR NR
5 0 0 0 0 0 4
6 NR NR NR NR NR NR
7 1 2 0 2 1 0
8 0 0 1 0 0 2
Median 0 0.5 1 0 0 3
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Looking at the dosimetry results alone, GU toxicity rates 
would be expected to be acceptable. In the present study, 
the median urethra V120 was 0.15 ml and maximum 
0.36 ml (Table 2). RTOG 0321 reported a mean urethral 
V125 of 0.15 ml and maximum 0.94 ml, and an acute GU 
toxicity grade ≥ 2 rate of 10% [27]. Urethral dose was also 
found to be the most predictive of GU toxicity in that trial 
[16]. Although the size and duration of the study are in-
sufficient to evaluate disease outcomes, the results were 
encouraging with no biochemical failures after a median 
PSA follow-up of 4.9 years. 
HDR brachytherapy has the relative advantage of 
adaptive treatment planning. Our experience in the pres-
ent study and others indicate that a free-hand inverse 
planning technique allows for sufficient dose modula-
tion to accommodate DIL boost without violating OAR 
constraints [42]. HDR brachytherapy has been previ-
ously used for intraprostatic DIL boosts with low tox-
icity reported. Borghede et al. treated 50 patients with 
50 Gy EBRT followed by two fractions of 10 Gy using 
HDR brachytherapy, with dose escalation to 15 Gy per 
fraction in biopsy-verified tumor areas in 30 patients [43]. 
Disease-free survival was 96% at a mean follow-up of 45 
months, with 8% grade 3 urinary toxicity and no high-
grade GI toxicity by RTOG criteria. Two other more re-
cent studies have reported the use of HDR brachytherapy 
to dose-escalate MRI-defined DIL. Gomez-Iturriaga et al. 
treated 15 patients with hypofractionated EBRT (37.5 Gy 
in 15 fractions), followed by a 15 Gy single fraction HDR 
brachytherapy boost [40]. Using inverse-planning, they 
achieved 131-151% DIL dose escalation while maintaining 
a conservative urethral maximum dose of 115%, and rectal 
V70 < 1 ml. DIL volumes were similar to the present study, 
suggesting DIL dose escalation with more conservative 
OAR constraints is still possible. They reported 27% grade 
2 GU toxicity and no grade 3 toxicity by CTCAE criteria. 
Vigneault et al. treated 19 patients with intermediate-risk 
prostate cancer with 45 Gy in 25 fractions EBRT followed 
by a 15 Gy single fraction HDR brachytherapy boost [39]. 
A single MRI-defined DIL per patient was dose-escalated 
to only 120%, although the DIL tended to be larger than 
in the present study. In that study, 16% of patients had 
acute grade 2 GU toxicity and one patient had acute grade 
3 GU toxicity by RTOG criteria. There was no late grade 3 
or higher toxicity. Early disease outcomes were promising 
with 95% biochemical control at 5 years. 
The greatest limitation of the present study is the 
small size, with only 8 protocol eligible patients. The pri-
mary reasons for low enrollment were concurrent com-
peting trials and the specification of no ADT before MRI 
spectroscopy, as many patients were referred having al-
ready started ADT. This restriction was enforced due to 
the known effects of ADT on MRSI sensitivity [26]. Since 
the design of this trial, there has been increased stan-
dardization of prostate multi-parametric MRI (mp-MRI) 
incorporating diffusion weighted imaging, dynamic con-
trast enhanced imaging as well as MRSI, resulting in the 
PI-RADS system [44]. Including other MRI modalities, it 
allows for DIL identification even within 3-4 months of 
starting ADT [45,46], which should be considered in de-
sign of future trials. 
Another key limitation of the present study was 
the potential for inaccurate localization of the DIL on the 
treatment planning CT. One component of this error is the 
uncertainty of image registration between MRSI (with en-
dorectal coil) and CT (no endorectal coil). Using non-lin-
ear registration to an intermediate MR image without 
endorectal coil before registering to CT, our image regis-
tration error is estimated at < 2 mm [28,29]. Another com-
ponent of the error is anatomic changes to the prostate 
due to ADT during the period between MRSI and treat-
ment planning (median 10.9 weeks in this study). ADT 
is effective at decreasing prostate volume and has been 
used as a treatment for benign prostatic hypertrophy 
[47]. Changes in prostate size between MRSI and plan-
ning CT could create registration errors that would not be 
corrected for by rigid-body registration, and this was not 
examined in our study. One possible solution to this com-
ponent of error would be obtaining the MRSI at the time 
of treatment, potentially as part of MRI-based treatment 
planning [48]. Despite the potential for inaccurate DIL lo-
calization in this study, no planning margin around the 
DIL was used. This was considered acceptable because 
the remainder of the prostate was still receiving a ther-
apeutic dose, and is consistent with other studies using 
HDR brachytherapy for DIL dose-escalation [39,40,49]. 
Conclusions 
Focal dose escalation to MRSI-defined DIL is feasible 
using inverse-planned HDR brachytherapy. Treatment 
toxicity met pre-defined thresholds, although the study 
was inconclusive due to low accrual. Patient-reported uri-
nary symptoms attributable to treatment were generally 
near baseline by 6 months after treatment. Biochemical 
disease control was 100% at a median 4.9 years follow-up, 
but larger studies with longer follow-up are needed. 
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